Last reviewed · How we verify

NCT05260463

LOQTEQ® Antibacterial Pre-Market Study

Completed NA Last updated 18 September 2025
What this trial tests

NA trial testing Implantation in Fractures, Open in 203 participants. Completed in 4 August 2025.

Timeline
9 December 2021
Primary endpoint
4 August 2025
4 August 2025

Quick facts

Lead sponsoraap Implantate AG
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment203
Start date9 December 2021
Primary completion4 August 2025
Estimated completion4 August 2025
Sites13 locations across Germany

Drugs / interventions tested

Conditions studied

Sponsor

aap Implantate AG

Who can join

18 and older, any sex, with Fractures, Open or Fractures, Closed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

aap001 is a randomized, controlled, subject-blinded, multi-center study to show the safety of the LOQTEQ® antibacterial silver-coated system is non-inferior in comparison with the uncoated LOQTEQ® system

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Silver-coated versus uncoated locking plates in subjects with fractures of the distal tibia: a randomized, subject and observer-blinded, multi-center non-inferiority study.
    Schoder S, Lafuente M, Alt V. · · 2022 · cited 4× · PMID 36456987 · DOI 10.1186/s13063-022-06919-0

Verify or expand the search:

Other trials of Implantation

Trials testing the same drug.

Other recruiting trials for Fractures, Open

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05260463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing